Clinical Trials Browser

Non-Muscle Invasive Bladder Neoplasms

NCT06919965 2026-03-13

MoonRISe-3

Phase 3 Recruiting

220 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07424287 2026-02-20

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Phase 3 Not yet recruiting

236 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06774131 2026-01-16

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

Phase 3 Recruiting

70 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06331299 2026-01-15

UTOPIA

Phase 3 Active not recruiting

99 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02106572 2025-07-23

TIM

Phase 3 Active not recruiting

548 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04241185 2024-11-25

MK-3475-992

Phase 3 Active not recruiting

520 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05243550 2024-11-04

ENVISION

Phase 3 Active not recruiting

240 enrolled 20 charts 1 FDA

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05136898 2024-09-19

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

Phase 3 Completed

8 enrolled 18 charts

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04688931 2024-06-06

ATLAS

Phase 3 Terminated

282 enrolled 29 charts

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02793128 2020-12-22

Olympus

Phase 3 Completed

71 enrolled 16 charts 2 FDA

Genitourinary

Carcinoma, Carcinoma, Transitional Cell

NCT04006691 2020-05-07

Retreatment

Phase 3 Withdrawn

Genitourinary

Carcinoma, Carcinoma, Transitional Cell

NCT03335059 2020-04-15

RITE-USA

Phase 3 Terminated

5 enrolled

Genitourinary

Urinary Bladder Neoplasms, Disease

NCT02982395 2019-08-30

Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC

Phase 3 Terminated

36 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

Clinical Trials

SunRISe-5

MoonRISe-3

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

UTOPIA

TIM

MK-3475-992

ENVISION

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

ATLAS

Olympus

Retreatment

RITE-USA

Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC